HC Wainwright Issues Pessimistic Forecast for Emergent Biosolutions (NYSE:EBS) Stock Price

Emergent Biosolutions (NYSE:EBS) had its price target reduced by equities researchers at HC Wainwright from $15.00 to $12.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 44.75% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings cut shares of Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.00.

Emergent Biosolutions Trading Down 1.8%

NYSE EBS opened at $8.29 on Monday. The firm has a market cap of $435.39 million, a P/E ratio of 9.87 and a beta of 2.41. The company has a debt-to-equity ratio of 1.09, a current ratio of 5.01 and a quick ratio of 2.41. The stock’s 50-day moving average is $11.29 and its 200-day moving average is $10.41. Emergent Biosolutions has a one year low of $4.02 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.54). Emergent Biosolutions had a net margin of 7.08% and a return on equity of 15.86%. The business had revenue of $148.70 million during the quarter, compared to analyst estimates of $217.50 million. Sell-side analysts anticipate that Emergent Biosolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Zacks Investment Management acquired a new position in shares of Emergent Biosolutions during the 4th quarter worth about $141,000. Millennium Management LLC raised its holdings in Emergent Biosolutions by 205.4% during the fourth quarter. Millennium Management LLC now owns 237,674 shares of the biopharmaceutical company’s stock worth $2,938,000 after acquiring an additional 159,850 shares in the last quarter. Aristeia Capital L.L.C. acquired a new position in Emergent Biosolutions during the fourth quarter valued at approximately $345,000. Schonfeld Strategic Advisors LLC acquired a new position in Emergent Biosolutions during the fourth quarter valued at approximately $283,000. Finally, Abel Hall LLC bought a new position in Emergent Biosolutions in the fourth quarter valued at approximately $129,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.